CJC-1295 no DAC Dosage, half-life & reference guide

Week by week.

What to expect in the first 8 weeks

Onset

1–2 weeks

Peak effect

8–12 weeks

Duration

8–12 weeks

1. Day 1–14Community

   Sleep usually moves first

   Commonly reported first: deeper sleep and vivid dreams. The short action is the point of the no-DAC form: sharp GH pulses rather than a raised baseline.

   The science

   Mechanism: a GHRH-receptor agonist that amplifies GH release by activating GHRH receptors on pituitary somatotrophs. Countering somatostatin is what GHRPs like ipamorelin add, which is why the two are paired (Ghigo 1997). The short action avoids continuous receptor occupancy.

   Sources

   • Ghigo et al. (1997)

   Updated Sep 2026

2. Day 14–28Community

   Recovery is quicker, skin looks better

   Commonly reported: faster recovery, and skin that looks tighter and better hydrated. IGF-1 rises only modestly with the no-DAC form, though that hasn't been measured in people.

   The science

   Unlike CJC-1295 WITH DAC (5.8–8.1-day half-life, IGF-1 up 1.5–3x for 9–11 days; Teichman 2006), the no-DAC version is meant to keep IGF-1 milder, but its effect hasn't been measured in humans. In a human study, pulsed GH raised fat breakdown more than continuous GH, which raised IGF-1 more (Surya 2009).

   Sources

   • Teichman et al. (2006)
   • Surya et al. (2009)

   Updated Sep 2026

3. Day 28–56Community

   Body composition starts shifting

   Commonly reported in weeks 4 to 8: visible body-composition changes, more lean mass and modest fat loss, with sleep strong and consistent.

   The science

   No controlled human body-composition trial exists for CJC no DAC; the expectation rests on GHRH physiology (IGF-1, fat breakdown, lean mass) and user reports.

   Updated Sep 2026

4. Day 56–84Community

   Cycle endpoint

   Community convention is 8–12 weeks on, 4–8 off — but no RCT has defined a real endpoint here. GHRH analogs amplify your own pulses rather than overriding them, so the continuous-use case is defensible if labs stay stable. Holding, maintenance, or a break are all within reasonable practice; many find gains hold through an off-cycle if sleep and training don't slide.

   The science

   CJC-1295 isn't FDA-approved, and FDA has flagged it for possible immune reactions and serious adverse events. Continuous dosing hasn't been studied for long-term safety; the 8–12 week on / 4–8 week off convention is community-driven conservative practice, not trial-guided.

   Updated Sep 2026

5. Any dayClinical

   What CJC-1295 no DAC is built on

   The no-DAC version is the short-acting counterpart of the DAC version, meant for pulse-like dosing. GHRH-plus-GHRP synergy has been shown in human GH studies since 1990, which is why the ipamorelin stack is the go-to; the no-DAC form itself has no published human studies.

   The science

   DAC version (Teichman 2006, J Clin Endocrinol Metab): 2–10x GH increase, 1.5–3x IGF-1 sustained for 9–11 days per injection. The no-DAC version (Mod GRF 1-29) is chosen by users who want shorter, pulse-like dosing. No trial of the specific Ipa+CJC no-DAC combo exists, but the GHRH+GHRP synergy is well established (Bowers 1990).

   Sources

   • Teichman et al. (2006)
   • Bowers et al. (1990)

   Updated Sep 2026

6. With IpamorelinCommunity

   The core GH stack

   The foundational GH stack: CJC-1295 amplifies each GH pulse and ipamorelin triggers it without raising cortisol (in animal studies), so together they give a larger GH response than either alone. Commonly reported: deeper sleep and better recovery than either alone.

   The science

   Mechanism: a GHRH analog (CJC) plus a GHRP (Ipa) releases more GH than the sum of each alone, a synergy well established for the two drug classes. CJC-1295 with DAC raised GH 2- to 10-fold (Teichman 2006); the no-DAC form hasn't been measured in humans. Users commonly co-inject them from one syringe; no compatibility study has been published.

   Sources

   • Teichman et al. (2006)
   • Ishida et al. (2020)

   Updated Sep 2026

7. Any dayClinical

   Where CJC-1295 sits in the GH family

   Think of the GH-secretagogue family in two halves: the GHRH side that lifts the baseline and the GHRP side that fires the pulse. CJC-1295 (no DAC) is a short-acting GHRH analog (its human half-life hasn't been measured), meant to amplify your own pulse — which is why it's paired with a GHRP like Ipamorelin instead of run alone. Sermorelin is the shorter-lived, gentler cousin; the with-DAC version is the long-acting one, which raises baseline GH while pulses continue.

   The science

   CJC-1295 no DAC (Mod GRF 1-29) is a short-acting GHRH-receptor agonist that preserves pulsatile GH architecture; the with-DAC version binds albumin for a 6–8 day half-life and raises baseline GH while pulses continue (Ionescu 2006). Compared with Sermorelin (native GHRH 1-29, ~11–12 min half-life, more degradation-prone), the four substitutions in Mod GRF 1-29 confer enzymatic resistance and a cleaner pulse. Positioning only — drawn from established pharmacology, no new claims.

   Sources

   • Teichman et al. (2006)
   • Ionescu & Frohman (2006)

   Updated Sep 2026

Swipe for more ›

Mixing and a typical run.

Safety.

Goes with.

• Ipamorelin
• Sermorelin

• In the GH Pulse + Repair stack

  Body composition, GH optimization & recovery

  With Ipamorelin and BPC-157

• In the CJC-1295 + Ipamorelin stack

  Classic GH pulse stack — CJC-1295 no DAC + Ipamorelin

  With Ipamorelin

Compared with.

• CJC-1295 no DAC vs Ipamorelin
• CJC-1295 with DAC vs CJC-1295 no DAC

Questions people ask.

Research.

Reference.

Cadence

2–3× daily

2–3x daily

Half-life

~30 min

~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes)

Research basis

●●● Moderate

Animal studies + some human data